Clinical Trial Update: Clinical Study of Cardiomyopeptidin on Postoperative Ischemia-reperfusion Injury in Patients With Primary PCI [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for Cardiomyopeptidin in patients undergoing primary PCI, focusing on myocardial survival area and left ventricular ejection fract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemia-reperfusion Injury
• Myocardial Infarction

Drugs mentioned

• Cardiomyopeptidin (cardiomyopeptidin)

Snippet

Sponsor: Dalian Zhen-Ao Bio-Tech Co., Ltd. | Conditions: Survival Myocardial Area After Acute Myocardial Death, Left Ventricular Ejection Fraction | Phase 4 | Status: UNKNOWN